Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin Announces Proposed Public Offering of American Depositary Shares
MYSTIC, Conn. and DUBLIN , Jan. 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it intends to offer for sale its American Depositary Shares in an underwritten
View HTML
Toggle Summary Amarin to Present at the 29th Annual J.P. Morgan Healthcare Conference
MYSTIC, Conn. and DUBLIN , Jan. 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2011 at 1:00pm PST . The conference will be held at the Westin St.
View HTML
Toggle Summary Amarin Completes Patient Randomization in Phase 3 ANCHOR Trial
Study Designed to Position AMR101 as First-in-Class Drug for Treating High Triglyceride Levels in Statin-Treated Patients with Mixed Dyslipidemia;ANCHOR Trial Studies a Separate Indication for AMR101 than Studied in Recently Reported Phase 3 MARINE Trial
View HTML
Toggle Summary Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
MYSTIC, Conn. and DUBLIN , Dec. 3, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 3:00pm PST .
View HTML
Toggle Summary Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo
- Largest controlled therapeutics trial in patients with very high triglycerides- Trial conducted in accordance with Special Protocol Assessment with FDA- NDA submission moved forward to 2011Conference call and Webcast scheduled for 8:30 a.m. EST (1:30 p.m. GMT) today
View HTML
Toggle Summary Amarin to Host Conference Call at 8:30 a.m. EST on November 29, 2010, to Discuss Top-Line Results of Phase 3 MARINE Study of AMR101 in Patients with Very High Triglycerides
MARINE Study is Largest Controlled Therapeutic Trial Ever Conducted in Patients with Very High Triglycerides
View HTML
Toggle Summary Amarin Corporation Appoints Kristine Peterson to Board of Directors
DUBLIN and MYSTIC, Conn. , Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the appointment of Kristine Peterson to its board of directors. Ms.
View HTML
Toggle Summary Amarin to Present at Lazard Capital Markets Annual Healthcare Conference
DUBLIN and MYSTIC, Conn. , Nov. 15, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 3:10pm .
View HTML
Toggle Summary Amarin Reports Third Quarter 2010 Financial Results and Positively Updates Phase 3 Guidance
-Phase 3 milestones moved ahead into 2010 for report of top line results of MARINE trial and completion of ANCHOR trial randomization-Conference call today at 11:00 AM Eastern Time
View HTML
Toggle Summary Amarin Corporation Announces Senior Management Changes
-Conference call today at 11:00 AM Eastern Time-
View HTML

Amarin Corporation